Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-07-01 / Immunotherapy 2011 Jul;3(7):805-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-07-01 / Immunotherapy 2011 Jul;3(7):805-72011-07-01 00:00:002019-02-15 08:52:17Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-28 / Cancer 2012 Jan;118(1):180-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-28 / Cancer 2012 Jan;118(1):180-72011-06-28 00:00:002011-06-28 00:00:00Reirradiation and hyperthermia for radiation-associated sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:65https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:652011-06-17 00:00:002019-02-15 08:45:33Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-91https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-912011-06-15 00:00:002019-02-15 08:52:52Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-15 / J Cancer 2011;2:357-9https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-15 / J Cancer 2011;2:357-92011-06-15 00:00:002019-02-15 08:52:49Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 2533)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 2533)2011-06-04 00:00:002011-06-04 00:00:00A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)2011-06-04 00:00:002011-06-04 00:00:00Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-403https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-4032011-06-03 00:00:002019-02-15 08:40:03Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002011-06-01 / J. Immunother. 2011 Jun;34(5):409-18https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2011-06-01 / J. Immunother. 2011 Jun;34(5):409-182011-06-01 00:00:002019-02-15 08:36:02PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
Reirradiation and hyperthermia for radiation-associated sarcoma
Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages
Prostate cancer immunotherapy
Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
Recent advances in immunotherapy for the treatment of prostate cancer
Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
Pilotażowe badanie immunoterapii w mięsakach dziecięcych wysokiego ryzyka.
Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design